Covestor’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13K Buy
336
+45
+15% +$1.42K 0.01% 1376
2026
Q1
$8K Sell
291
-29
-9% -$951 0.01% 1565
2025
Q4
$12K Buy
320
+33
+11% +$1.08K 0.01% 1486
2025
Q3
$8K Sell
287
-103
-26% -$3.55K ﹤0.01% 1730
2025
Q2
$13K Buy
390
+78
+25% +$2.51K 0.01% 1408
2025
Q1
$11K Buy
312
+24
+8% +$860 0.01% 1438
2024
Q4
$10K Sell
288
-10
-3% -$344 0.01% 1535
2024
Q3
$12K Sell
298
-69
-19% -$2.42K 0.01% 1436
2024
Q2
$11K Buy
367
+4
+1% +$120 0.01% 1465
2024
Q1
$12K Sell
363
-5,026
-93% -$161K 0.01% 1447
2023
Q4
$174K Buy
5,389
+735
+16% +$20.5K 0.12% 205
2023
Q3
$153K Buy
4,654
+217
+5% +$7.53K 0.12% 206
2023
Q2
$156K Buy
4,437
+1,904
+75% +$65.7K 0.12% 216
2023
Q1
$83K Buy
2,533
+974
+62% +$44.4K 0.07% 482
2022
Q4
$86K Sell
1,559
-87
-5% -$4.78K 0.07% 471
2022
Q3
$73K Buy
1,646
+1,638
+20,475% +$79.9K 0.06% 531
2022
Q2
$0 Sell
8
-4
-33% -$180 ﹤0.01% 2111
2022
Q1
$1K Sell
12
-8
-40% -$326 ﹤0.01% 1846
2021
Q4
$1K Buy
+20
New +$797 ﹤0.01% 1780

Other funds holding HRMY

Covestor's HRMY Position: Q2 2026 in Review

Covestor increased its Harmony Biosciences (HRMY) stake by 15% in Q2 2026, buying an estimated $1.42K and bringing the position to 336 shares worth $13K. The position accounts for 0.01% of the portfolio, ranked #1376.

Covestor first reported a position in HRMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $174K in Q4 2023. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Covestor held 336 shares of Harmony Biosciences worth $13K as of Q2 2026.
  • Covestor bought 45 Harmony Biosciences shares in Q2 2026, an estimated $1.42K.
  • Harmony Biosciences made up 0.01% of Covestor's portfolio in Q2 2026, its #1376 holding.
  • Covestor first reported a position in Harmony Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Harmony Biosciences position peaked at $174K in Q4 2023.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.